Lee Bomee, Keum Bora, Hong Sung Noh, Kim Hyun Gun, Im Jong Pil, Na Soo-Young, Kwak Min Seob, Nam Kwangwoo, Byeon Jeong-Sik
Department of Internal Medicine, Division of Gastroenterology and Hepatology, Korea University College of Medicine, Seoul, South Korea.
Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
J Gastroenterol Hepatol. 2025 Sep;40(9):2248-2257. doi: 10.1111/jgh.70006. Epub 2025 Jul 24.
High-volume polyethylene glycol (PEG) solutions are associated with low patient compliance, whereas low-volume alternatives pose higher risks of adverse events. We compared a new 0.8-L PEG-ascorbic acid solution containing simethicone to a 2-L PEG-ascorbic acid solution.
In this prospective, investigator-blinded study, 137 outpatients from five centers were randomized into three groups: Group A (0.8-L PEG-ascorbic acid with a split-dose regimen), Group B (0.8-L PEG-ascorbic acid on the same day as the colonoscopy), and Group C (2-L PEG-ascorbic acid with a split-dose regimen). The primary outcome was the cleansing efficacy, assessed using the Harefield Cleansing Scale (HCS). Secondary outcomes included bubble score, polyp and adenoma detection rates, patient satisfaction, tolerability, and safety.
All groups achieved 100% successful preparation (HCS grades A and B). Group B had a higher HCS grade in the ascending colon than Group C (3.2 vs. 3.0, p = 0.01). Groups A and B showed better bubble scores than Group C (p < 0.0001). Polyp and adenoma detection rates were similar across the groups. Group B demonstrated the highest satisfaction score (139.1 ± 76.7), followed by Group A (129.8 ± 64.9) and Group C (125.6 ± 60.0), with no significant differences. The tolerability and safety parameters were similar between the groups.
The novel 0.8-L PEG-ascorbic acid solution was effective, safe, and highly tolerable, showing noninferiority to the 2-L PEG-ascorbic acid solution. The same-day regimen showed a tendency toward better cleansing efficacy in the ascending colon and higher patient satisfaction.
大容量聚乙二醇(PEG)溶液会导致患者依从性低,而小容量替代品会带来更高的不良事件风险。我们将一种含西甲硅油的新型0.8升PEG - 抗坏血酸溶液与一种2升PEG - 抗坏血酸溶液进行了比较。
在这项前瞻性、研究者设盲的研究中,来自五个中心的137名门诊患者被随机分为三组:A组(0.8升PEG - 抗坏血酸,采用分剂量方案)、B组(在结肠镜检查当天服用0.8升PEG - 抗坏血酸)和C组(2升PEG - 抗坏血酸,采用分剂量方案)。主要结局是使用哈雷菲尔德清洁量表(HCS)评估的清洁效果。次要结局包括气泡评分、息肉和腺瘤检出率、患者满意度、耐受性和安全性。
所有组的准备均成功(HCS分级为A和B)。B组升结肠的HCS分级高于C组(3.2对3.0,p = 0.01)。A组和B组的气泡评分优于C组(p < 0.0001)。各组的息肉和腺瘤检出率相似。B组的满意度得分最高(139.1±76.7),其次是A组(129.8±64.9)和C组(125.6±60.0),差异无统计学意义。各组之间的耐受性和安全性参数相似。
新型0.8升PEG - 抗坏血酸溶液有效、安全且耐受性高,显示出与2升PEG - 抗坏血酸溶液非劣效。当日方案在升结肠的清洁效果和患者满意度方面有更好的趋势。